slide1
Download
Skip this Video
Download Presentation
February 2013

Loading in 2 Seconds...

play fullscreen
1 / 34

February 2013 - PowerPoint PPT Presentation


  • 94 Views
  • Uploaded on

February 2013. BioGaia – a healthcare company in probiotics. Vision : BioGaia´s vision is to improve the health of people around the world by offering first class probiotic products.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' February 2013' - scot


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
biogaia a healthcare company in probiotics
BioGaia – a healthcare company in probiotics

Vision: BioGaia´s vision is to improve the health of people around the world by offering first class probiotic products.

Business concept: BioGaia´s concept is to develop, market and sell well documented probiotic products worldwide in the form of innovative and appealing dietary supplements and food products.

Probiotics:Live microorganisms which when administered in adequate amounts confer a documented health benefit.

biogaia
BioGaia
  • Founded in 1990
  • Probiotics (strains of Lactobacillus reuteri)
  • 79 employees (Stockholm 31, Lund 23, Eslöv 16, Raleigh 2, Hiroshima 6, Shanghai 1)
  • Two segments: Finished consumer products/Component products
  • More than 100 clinical studies
  • Products in 60 markets through distributors
  • Contract manufacturing
  • TwoPac (50% owned)
  • Holds over 200 patents in 25 families
change of focus
Change of focus

Dietary Supplements

Infant formula

Functional Foods / Dairies

Animal Health

1990

1995

2000

2005

2010

biogaia brand
BioGaia Brand
  • Branding for Health professionals
  • Sold in over 40 countries
  • 45% of sales of finished products (incl. co-

branding 51%)

  • Build value, less dependence on distributors and patents
competition strategy
Competition Strategy
  • Clinical trials of high quality
  • Attractive and unique formulations and packaging solutions
  • Strong partner support
slide10

Clinical trials supporting the use of BioGaia Probiotics with L. reuteri – including the strains L. reuteri Protectis, Prodentis and Gastrus

  • Completed clinical trialsNov. 2012
  • 108 trials in 8600 individuals
  • whereof:
    • 76 randomised, double-blind / blind, placebo-controlled studies in 6 800 subjects
    • 32 open studies in 1 770 subjects
    • 35 studies in 0-3y in 3 900 subjects

Results are published in67scientific articles and 5 doctoral theses

product indications overview
Product Indications Overview

L. reuteri DSM 17938 (ATCC 55730)

  • BioGaia ProTectis (82*)

Gut Motility

Diarrhoea

Neonatal Intensive Care

Regurgitation

Necrotising Enterocolitis

Prevention

Gingivitis/plaque

Infantile colic

Acute Gastroenteritis

Periodontitis

Antibiotic AssociatedDiarrhoea (AAD)

Constipation

Feeding tolerance

Functional abdominal

Pain (FAP)

  • BioGaia ProDentis (22*)

L. reuteri DSM 17938 & L. reuteri ATCC PTA 5289

L. reuteri DSM 17938 & L. reuteri ATCC PTA 6485

  • BioGaia Gastrus (2*)

Gum Integrity

Stomach Health

H. Pylori infection/inflammation

H. pylori side effects

* Number of completedclinical studies byNov 2012

health protection by l reuteri protectis in children
Health protection by L. reuteri Protectisin children

Children (4-10 m) with increasedrisk for infection12 weekssupplementationin baby formula

Weizman et al., Pediatr 115; 5-9 (2005)

health economics of l reuteri protectis supplementation
Health economics of L. reuteri Protectissupplementation

Children (4-10 m) with increasedrisk for infection12 weekssupplementationin baby formula

Weizman et al., Pediatr 115; 5-9 (2005)

slide14

L. reuteri Protectisprevents antibiotic- associated diarrhoea

Adults in hospital on antibiotics

Supplemented with

L. reuteri Protectisor placebo for 4 weeks

Cimperman et al. ASPEN meeting February 2009

slide15

L. reuteri Protectisreduces infantile colic

**

***

Crying time (median; mins/day)

***

***

**

***

p< 0.01

p< 0.001

Days of supplementation

Savino et al. Pediatr Res 58: 411 (2005)

Savino et al. Pediatr, in press (2006)

biogaia product portfolio
BioGaia product portfolio

ProTectis

Digestive Health

ProDentis

OralHealth

Gastrus

Stomach Health

ProTectis

Baby

ProTectis D3

Baby

ProTectis

Junior

ProTectis

Baby/Junior

ProTectis

ProDentis

ProDentis

Gastrus

Drops

Lozenges

Tablets

Tablets

ORS

Tablets

Drops

Drops

strong partner support
Strong partner support
  • Clinical trials
  • Marketing and PR support
  • BioGaia Academy
  • Web site
  • Participation in conferences
  • Speakers at symposiums
  • Education of sales representatives
competitors
Competitors

Culture suppliers

  • Chr Hansen
  • Danisco
  • InstitutRosellLallemand (France)

Probiotic strains

  • Valio (Finland)
  • Probi (Sweden)

Functional Foods

  • Danone
  • Yakult

Pharma

  • Merck (Germany)
  • Novartis
  • Sanofi Aventis
  • Ferrosan (Pfizer)

Other

  • P&G
  • Local competitors
launches and planned launches
Launches and planned launches
  • Drops: Launched in 56 countries (contracts but not launched in 15countries)
  • Tablets: Launched in 47 countries (contracts but not launched in 20 countries)
  • ORS: Launched in 6 countries (contracts but not launched in 7 countries)
  • Oral health products: Launched in 19 countries (contracts but not launched in 4 countries)
key events 2012
Key events 2012
  • BioGaia extends collaboration with Nestlé
  • Agreement with Gerber for sales of drops and ORS in United States
  • Agreement with Nestlé for sales of drops in Mexico
  • Agreement for oral health products in Czech Republic, the Benelux countries, South Africa, Singapore and Israel
  • Agreement for tablets and drops in Taiwan and Pakistan
key events 2012 cont d
Key events 2012 (cont’d)
  • Study in type 2 diabetes started
  • 19 Published studies:
  • For example:
  • Study on reduction of diarrhoea in children
  • New confirming study on colic
  • Two studies on NEC in premature infants
  • Study on Periodontitis
nestl agreement
Nestlé Agreement
  • Sale of licence for EUR 50.8 (EUR 40 million paid and accounted for in q1 2012)
  • Further projects will be announced closer to launch (USA and Mexico)
  • Revenue from Nestlé is estimated in 2012 (excluding the up-front payment) to 50% of sales during 2011, in 2013 close to 2011 level and from 2014 and forward more than 2011
sales development excl licence revenue 2012
Sales development (excl. licence revenue 2012)

+33%

-8% *)

+36%

Average growth: 24%

*) Excluding licence revenue of SEK 356 million from Nestlé

sales development finished consumer products
Sales development Finished consumer products

+10%

+39%

+46%

Average growth: 27%

the board
The Board

Jörgen Thorball

Inger Holmström

David Dangoor

Chairman

Paula Zeilon

Jan Annwall

Stefan Elving

Thomas Flinck

major shareholders 31 december 2012
Major Shareholders 31 December 2012

Total number of shareholders 31 December 2012: 7,384

Foreign owners: 43% of capital (31% of votes)

present focus
Present focus
  • Continued focus on BRIC-countries and US
  • A number of development projects with Nestlé
  • Business model for Oral Health
ad